GioTag: Real-world Data Study on Sequential Therapy With Gi(l)Otrif/ Afatinib as First-line Treatment Followed by Osimertinib in Patients With EGFR Mutation Positive Advanced Non-small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 22 Oct 2018
At a glance
- Drugs Afatinib (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms GioTag
- Sponsors Boehringer Ingelheim
- 22 Oct 2018 According to a Boehringer Ingelheim media release, results from this trial will be presented at an upcoming medical conference later this year.
- 22 Oct 2018 Results presented in a Boehringer Ingelheim media release.
- 19 Oct 2018 According to a Boehringer Ingelheim media release, results from this trial were published today in Future Oncology Journal.